Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.52 |
| ▸ | CES1 | P23141 | 2/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | TDO2 | P48775 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6202122 | 0.82 | CES2 (0.56) | CES2CES1HDAC4HDAC7HDAC5 | |
| SCHEMBL6202123 | 0.81 | CES2 (0.55) | CES2CES1HDAC4HDAC7HDAC5 | |
| SCHEMBL723341 | 0.81 | HDAC4 (0.47) | CES2CES1HDAC4HDAC7HDAC5 | |
| SCHEMBL11603896 | 0.81 | CES2 (0.55) | CES2CES1HDAC4HDAC7HDAC5 | |
| SCHEMBL227352 | 0.81 | CES2 (0.55) | CES2CES1HDAC4HDAC7HDAC5 | |
| SCHEMBL4433928 | 0.81 | HDAC4 (0.47) | CES2CES1HDAC4HDAC7HDAC5 | |
| SCHEMBL3808194 | 0.79 | HDAC4 (0.46) | CES2CES1HDAC4HDAC7HDAC5 | |
| SCHEMBL5081061 | 0.79 | CES2 (0.53) | CES2CES1HDAC4HDAC7HDAC5 | |
| SCHEMBL6204304 | 0.79 | HDAC4 (0.50) | CES2CES1HDAC4HDAC7HDAC5 | |
| SCHEMBL7783860 | 0.78 | CES2 (0.49) | CES2CES1HDAC4HDAC7HDAC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109810572-A | Inorganic nano material prints ink and its preparation method and application | 深圳TCL工业研究院有限公司 | 2019-05-28 | — | — | CN | claimed |
| CN-105143170-B | For treating the aromatic compounds of pulmonary fibrosis, liver fibrosis, fibrosis of skin and cardiac fibrosis being substituted | 普罗米蒂克医药SMT有限公司 | 2019-11-08 | — | — | CN | disclosed |
| CN-109810567-A | Inorganic nano material prints ink and its preparation method and application | TCL集团股份有限公司 | 2019-05-28 | — | — | CN | disclosed |
| CN-109810571-A | Inorganic nano material prints ink and its preparation method and application | TCL集团股份有限公司 | 2019-05-28 | — | — | CN | disclosed |
| CN-109810572-A | Inorganic nano material prints ink and its preparation method and application | 深圳TCL工业研究院有限公司 | 2019-05-28 | — | — | CN | disclosed |
| CN-109810573-A | Inorganic nano material prints ink and its preparation method and application | TCL集团股份有限公司 | 2019-05-28 | — | — | CN | disclosed |
| CN-109810570-A | Inorganic nano material prints ink and its preparation method and application | TCL集团股份有限公司 | 2019-05-28 | — | — | CN | disclosed |
| CN-109810574-A | Inorganic nano material prints ink and its preparation method and application | 深圳TCL工业研究院有限公司 | 2019-05-28 | — | — | CN | disclosed |
| CN-109810568-A | Inorganic nano material prints ink and its preparation method and application | TCL集团股份有限公司 | 2019-05-28 | — | — | CN | disclosed |
| CN-102532180-B | The little molecule of boracic | 安纳考尔医药公司 | 2016-06-29 | — | — | CN | disclosed |
| EP-2537845-B1 | 6H-DIBENZO[B,E]OXEPINE DERIVED NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2014-03-19 | — | — | EP | disclosed |
| CN-103479654-A | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS INC | 2014-01-01 | — | — | CN | disclosed |
| EP-2537845-A1 | 6H-dibenzo[B,E]oxepine derived nonsteroidal mineralocorticoid receptor antagonists | Eli Lilly and Company (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-2235007-B1 | 6H-DIBENZ0 [B, E] OXEPINE DERIVED NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2012-10-31 | — | — | EP | disclosed |
| US-7994164-B2 | Mineralocorticoid receptor antagonists and methods of use | ELI LILLY AND COMPANY (US) | 2011-08-09 | — | — | US | disclosed |
| EP-2235007-A1 | 6H-DIBENZ0 [B, E] OXEPINE DERIVED NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009085584-A1 | 6H-DIBENZ0 [B, E] OXEPINE DERIVED NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090163472-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS AND METHODS OF USE | ELI LILLY AND COMPANY | 2009-06-25 | — | — | US | disclosed |
| EP-1506175-A1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003097609-A1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDFG RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163472-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS AND METHODS OF USE | NR3C2, MC2R, REN | CES2 4373/4885CES1 2101/4885HDAC4 2256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.